Resverlogix Corp.
TSX : RVX

Resverlogix Corp.

October 03, 2005 09:00 ET

Resverlogix Reports ApoA1 Increase Across Animal Species

CALGARY, ALBERTA--(CCNMatthews - Oct. 3, 2005) - Resverlogix Corp. (TSX:RVX), announced today preclinical findings on its lead cardiovascular technology program NEXVAS™. The announcement of these research findings comes from an expanding body of information illustrating the feasibility of small molecule ApoA1 enhancement in multiple animal models for the potential treatment of cardiovascular disease and the regression of atherosclerosis.

These studies have found that in multiple animal models; transgenic mouse, rat, wild type mouse, and hamster, with a preliminary dosage range set, initial lead small molecules have exhibited increases of ApoA1 levels of up to 45%. The JAMA study reported in November 2003, illustrated for the first time regression of coronary atherosclerosis with ApoA1 (Milano) injections, with temporary elevated ApoA1 levels of approximately 10-15%. The company believes that persistent elevation of ApoA1 levels via NEXVAS™ molecules would likely exceed these increases of ApoA1, suggesting its fantastic potential for regression of atherosclerosis, the main underlying cause of cardiovascular disease.

"We are pleased to be able to share this exciting data with the investment and cardiovascular research community" said Dr. Jan Johansson, M.D., Ph.D., and Resverlogix Senior Vice President of Clinical Development. "The results of these experiments have contributed to the continued expansion and development of our in vitro and in vivo preclinical program. We believe that with the consistency in the animal models shown to date, our novel compounds illustrate properties likely to predict their significant effects in humans as ApoA1/HDL raisers, eventually rendering them effective products for treating cardiovascular disease."

These reported findings are a prelude to further expansion or the company's research efforts. The company will continue its lead optimization program utilizing proprietary delivery technologies and refined animal testing to further maximize NEXVAS™ ApoA1 efficacy.

As part of the ongoing RFP process with leading global life science organizations, detailed scientific results of this set of data are being exclusively provided to these companies under confidentiality agreements.

About Resverlogix Corp.

NEXVAS™ Technology: The primary focus for Resverlogix is the development of new technology designed to control cholesterol related diseases such as atherosclerosis (the buildup of plaque in the arteries). Existing drugs control the level of LDL ("bad cholesterol") in the body and have only illustrated the slowing of atherosclerosis. Resverlogix's NEXVAS™ program is developing proprietary technology that stimulates the body to produce ApoA1 protein, the primary component of HDL, which results in increased levels of HDL ("good cholesterol"). ApoA1/HDL has been proven to not just arrest but reverse atherosclerosis by reducing existing cholesterol deposits. Activating the body to enhance ApoA1 levels is the simplest physiological or natural approach to regulating HDL.

Cardiovascular disease is the leading cause of death in industrialized countries. The drugs that are currently used to control cholesterol can only slow the progress of atherosclerosis, and yet they are the biggest selling drugs in the world with a combined market of some U.S. $30 billion annually. Resverlogix's ApoA1 technology has the potential to capture and expand much of this market.

For a more detailed explanation about NEXVAS™ technology, please access the animation on the company website at http://resverlogix.com/nexvas-apoa1.htm.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.

The TSX does not accept responsibility for the adequacy or accuracy of this news release.

Contact Information